Mirabegron

• CAT Number: A000253
• CAS Number: 223673-61-8
• Molecular Formula: C21H24N4O2S
• Molecular Weight: 396.5
• Purity: ≥95%
• Target: Adrenergic Receptor
• Solubility: Soluble in DMSO > 10 mM
• Storage: -20°C
• IUPAC Name: 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide
• InChI: 1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
• InChIKey: PBAPPPCECJKMCM-IBGZPJMESA-N
• SMILES: C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O

Mirabegron (YM-178, trade name Myrbetriq, CAS 223673-61-8 ) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012. Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity.

Overview of Clinical Research

Mirabegron is a beta 3 adrenergic receptor agonist developed by Astellas Pharma and Johns Hopkins University. The Phase III clinical trials in Overactive bladder begins in 2020. 

Reference

1: Xu Y, Liu R, Liu C, Cui Y, Gao Z. Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder. Int Neurourol J. 2017 Sep;21(3):212-219. doi: 10.5213/inj.1734934.467. Epub 2017 Sep 12. PubMed PMID: 28954464; PubMed Central PMCID: PMC5636960.
2: Gibson W, MacDiarmid S, Huang M, Siddiqui E, Stölzel M, Choudhury N, Drake MJ. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. Eur Urol Focus. 2017 Sep 12. pii: S2405-4569(17)30200-6. doi: 10.1016/j.euf.2017.08.008. [Epub ahead of print] PubMed PMID: 28916436.
3: Wagg AS, Foley S, Peters J, Nazir J, Kool-Houweling L, Scrine L. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database. Int J Clin Pract. 2017 Oct;71(10). doi: 10.1111/ijcp.12996. Epub 2017 Sep 14. PubMed PMID: 28906080.
4: Yoshida M, Nozawa Y, Kato D, Tabuchi H, Kuroishi K. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder Aged ≥75 Years: Analysis of a Japanese Post-Marketing Study. Low Urin Tract Symptoms. 2017 Sep 12. doi: 10.1111/luts.12190. [Epub ahead of print] PubMed PMID: 28901041.
5: Engle JA, Fair C. Sirolimus and mirabegron interaction in a hematopoietic cell transplant patient. J Oncol Pharm Pract. 2017 Jan 1:1078155217726161. doi: 10.1177/1078155217726161. [Epub ahead of print] PubMed PMID: 28814193.
6: Ng DB, Espinosa R, Johnson SJ, Walker D, Gooch K. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States. J Med Econ. 2017 Sep 4:1-9. doi: 10.1080/13696998.2017.1367300. [Epub ahead of print] PubMed PMID: 28805473.
7: Kato D, Tabuchi H, Uno S. Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study. Low Urin Tract Symptoms. 2017 Aug 1. doi: 10.1111/luts.12188. [Epub ahead of print] PubMed PMID: 28762672.
8: Robinson D, Kelleher C, Staskin D, Mueller ER, Falconer C, Wang J, Ridder A, Stoelzel M, Paireddy A, van Maanen R, Hakimi Z, Herschorn S. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourol Urodyn. 2017 Jul 13. doi: 10.1002/nau.23315. [Epub ahead of print] PubMed PMID: 28704584.
9: Andersson KE. Pharmacology: Cardiovascular effects of mirabegron. Nat Rev Urol. 2017 Oct;14(10):587-588. doi: 10.1038/nrurol.2017.113. Epub 2017 Jul 11. PubMed PMID: 28695920.
10: Drake MJ, Nitti VW, Ginsberg DA, Brucker BM, Hepp Z, McCool R, Glanville JM, Fleetwood K, James D, Chapple CR. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int. 2017 Nov;120(5):611-622. doi: 10.1111/bju.13945. Epub 2017 Aug 2. Review. PubMed PMID: 28670786.